A Double-Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0, 800, or 1600 mg/Day of S-2367 Administered Orally Once Daily With a Reduced Calorie Diet in Obese Males and Females.

Trial Profile

A Double-Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0, 800, or 1600 mg/Day of S-2367 Administered Orally Once Daily With a Reduced Calorie Diet in Obese Males and Females.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2011

At a glance

  • Drugs Velneperit (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Shionogi USA
  • Most Recent Events

    • 24 Oct 2009 Results presented at the 2009 Annual Meeting of the North American Association for the Study of Obesity (NAASO 2009).
    • 24 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Feb 2009 Secondary endpoint analysis is ongoing, according to a Shionogi media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top